59214 Federal Register / Vol. 65, No. 193 / Wednesday, October 4, 2000 / Notices

This document was written by Lee

Scharf, ADR Specialist at the

Environmental Protection Agency, and

draws from the work of Cathy

Costantino and Christine SicklesMerchant as well as that of the

Administrative Conference of the

United States. See the Resources section

for cites.

[FR Doc. 00–25397 Filed 10–3–00; 8:45 am]

BILLING CODE 4410–AR–U

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

[DEA # 207P]

Controlled Substances: Proposed

Aggregate Production Quotas for 2001

AGENCY: Drug Enforcement

Administration (DEA), Justice.

ACTION: Notice of proposed year 2001

aggregate production quotas.

SUMMARY: This notice proposes initial

year 2001 aggregate production quotas

for controlled substances in Schedules I

and II of the Controlled Substances Act

(CSA).

DATES: Comments or objections must be

received on or before November 3, 2000.

ADDRESSES: Send comments or

objections to the Deputy Administrator,

Drug Enforcement Administration,

Washington, D.C. 20537, Attn.: DEA

Federal Register Representative (CCR).

FOR FURTHER INFORMATION CONTACT:

Frank L. Sapienza, Chief, Drug and

Chemical Evaluation Section, Drug

Enforcement Administration,

Washington, D.C. 20537, Telephone:

(202) 307–7183.

SUPPLEMENTARY INFORMATION: Section

306 of the CSA (21 U.S.C. 826) requires

that the Attorney General establish

aggregate production quotes for each

basic class of controlled substance listed

in Schedules I and II. This

responsibility has been delegated to the

Administrator of the DEA by Section

0.100 of Title 28 of the Code of Federal

Regulations. The Administrator, in turn,

has redelegated this function to the

Deputy Administrator of the DEA

pursuant to Section 0.104 of Title 28 of

the Code of Federal Regulations.

The proposed year 2001 aggregate

production quotas represent those

quantities of controlled substances that

may be produced in the United States in

2001 to provide adequate supplies of

each substance for: The estimated

medical, scientific, research, and

industrial needs of the United States;

lawful export requirements; and the

establishment and maintenance of

reserve stocks. These quotas do not

include imports of controlled

substances for use in industrial

processes.

In determining the proposed year

2001 aggregate production quotas, the

Deputy Administrator considered the

following factors: total actual 1999 and

estimated 2000 and 2001 net disposals

of each substance by all manufacturers;

estimates of 2000 year-end inventories

of each substance and of any substance

manufactured from it and trends in

accumulation of such inventories;

product development requirements of

both bulk and finished dosage form

manufacturers; projected demand as

indicated by procurement quota

applications filed pursuant to Section

1303.12 of Title 21 of the code of

Federal Regulations; and other pertinent

information.

Pursuant to Section 1303 of Title 21

of the Code of Federal Regulations, the

Deputy Administrator of the DEA will,

in early 2001, adjust aggregate

production quotas and individual

manufacturing quotas allocated for the

year based upon 2000 year-end

inventory and actual 2000 disposition

data supplied by quota recipients for

each basic class of Schedules I or II

controlled substance.

Therefore, under the authority vested

in the Attorney General by Section 306

of the CSA of 1970 (21 U.S.C. 826),

delegated to the Administrator of the

DEA by Section 0.100 of Title 28 of the

Code of Federal Regulations, and

redelegated to the Deputy Administrator

pursuant to Section 0.104 of Title 28 of

the Code of Federal Regulations, and the

Deputy Administrator hereby proposes

that the year 2001 aggregate production

quotas for the following controlled

substances, expressed in grams of

anhydrous acid or base, be established

as follows:

Basic class Proposed year

2001 quotas

Schedule I:

2,5-

Dimethoxyamphetamine 15,501,000

2,5-Dimethoxy-4-

ethylamphetamine

(DOET) .......................... 2

3-Methylfentanyl ................ 14

3-Methylthiofentanyl .......... 2

3,4-

Methylenedioxyamphetamine (MDA) ................... 25

3,4-Methylenedioxy-Nethylamphetamine

(MDEA) .......................... 30

3,4-

Methylenedioxymethamphetamine (MDMA) ....... 10

3,4,5-

Trimethoxyamphetamine 2

Basic class Proposed year

2001 quotas

4-Bromo-2,5-

Dimethoxyamphetamine

(DOB) ............................ 2

4-Bromo-2,5-

Dimethoxyphenethylamine (2–CB) ...................... 2

4-Methoxyamphetamine .... 201,000

4-Methylaminorex .............. 2

4-Methyl-2,5-

Dimethoxyamphetamine

(DOM) ............................ 2

5-Methoxy-3,4-

Methylenedioxyamphetamine ............................... 2

Acetyl-alphamethylfentanyl ............... 2

Acetyldihydrocodeine ........ 2

Acetylmethadol .................. 2

Allylprodine ........................ 2

Alphacetylmethadol ........... 7

Alpha-ethyltryptamine ....... 2

Alphameprodine ................ 2

Alphamethadol .................. 2

Alpha-methylfentanyl ......... 2

Alpha-methylthiofentanyl ... 2

Aminorex ........................... 7

Benzylmorphine ................ 2

Betacetylmethadol ............. 2

Beta-hydroxy-3-

methylfentanyl ............... 2

Beta-hydroxyfentanyl ........ 2

Betameprodine .................. 2

Betamethadol .................... 2

Betaprodine ....................... 2

Bufotenine ......................... 2

Cathinone .......................... 9

Codeine-N-oxide ............... 2

Diethyltryptamine .............. 2

Difenoxin ........................... 9,000

Dihydromorphine ............... 634,000

Dimethyltryptamine ........... 2

Gamma-hydroxybutyric

acid ................................ 15,000,000

Heroin ................................ 2

Hydroxypethidine .............. 2

Lysergic acid diethylamide

(LSD) ............................. 37

Marihuana ......................... 350,000

Mescaline .......................... 7

Methaqualone ................... 19

Methcathinone ................... 11

Morphine-N-oxide .............. 2

N,N-Dimethylamphetamine 7

N-Ethyl-lPhenylcyclohexylamine

(PCE) ............................. 5

N-Ethylamphetamine ......... 7

N-Hydroxy-3,4-

Methylenedioxyamphetamine ............................... 2

Noracymethadol ................ 2

Norlevorphanol .................. 2

Normethadone .................. 7

Normorphine ..................... 7

Para-fluorofentanyl ............ 2

Pholcodine ........................ 2

Porpiram ............................ 415,000

Psilocybin .......................... 2

Psilocyn ............................. 2

Tetrahydrocannabinols ...... 131,000

Thiofentanyl ....................... 2

Federal Register / Vol. 65, No. 193 / Wednesday, October 4, 2000 / Notices 59215

Basic class Proposed year

2001 quotas

Trimeperidine .................... 2

Schedule II:

1-Phenylcyclohexylamine .. 12

1-

Piperidinocyclohexanecarbonitrile (PCC) ............ 10

Alfentanil ........................... 3,000

Alphaprodine ..................... 2

Amobarbital ....................... 12

Amphetamine .................... 10,958,000

Cocaine ............................. 251,000

Codeine (for sale) ............. 43,248,000

Codeine (for conversion) .. 59,051,000

Dextropropoxyphene ......... 134,401,000

Dihydrocodeine ................. 272,000

Diphenoxylate ................... 401,000

Ecgonine ........................... 51,000

Ethylmorphine ................... 12

Fentanyl ............................ 440,000

Glutethimide ...................... 2

Hydrocodone (for sale) ..... 21,417,000

Hydrocodone (for conversion) ............................... 26,540,000

Hydromorphone ................ 1,409,000

Isomethadone ................... 12

Levo-alphacetylmethadol

(LAAM) .......................... 41,000

Levomethorphan ............... 2

Levorphanol ...................... 15,000

Meperidine ........................ 10,168,000

Methadone (for sale) ......... 8,347,000

Methadone (for conversion) ............................... 60,000

Methadone Intermediate ... 9,503,000

Methamphetamine ............ 2,226,000

850,000 grams of levodesoxyephedrine for

use in a non-controlled, non-prescription product;

1,325,000 grams for

methamphetamine for

conversion to a

Schedule III product;

and 51,000 grams for

methamphetamine (for

sale).

Methylphenidate ................ 14,957,000

Morphine (for sale) ............ 14,706,000

Morphine (for conversion) 117,675,000

Nabilone ............................ 2

Noroxymorphone (for sale) 25,000

Noroxymorphone (for conversion) .......................... 3,180,000

Opium ................................ 570,000

Oxycodone (for sale) ........ 46,680,000

Oxycodone (for conversion) ............................... 449,000

Oxymorphone .................... 264,000

Pentobarbital ..................... 22,037,000

Phencyclidine .................... 40

Phenmetrazine .................. 2

Phenylacetone .................. 10

Secobarbital ...................... 12

Sufentanil .......................... 1,000

Thebaine ........................... 65,596,000

The Deputy Administrator further

proposes that aggregate production

quotas for all other Schedules I and II

controlled substances included in

Sections 1308.11 and 1308.12 of Title 21

of the Code of Federal Regulations be

established at zero.

All interested persons are invited to

submit their comments and objections

in writing regarding this proposal. A

person may object to or comment on the

proposal relating to any of the abovementioned substances without filing

comments or objections regarding the

others. If a person believes that one or

more or these issues warrant a hearing,

the individual should so state and

summarize the reasons for this belief.

In the event that comments or

objections to this proposal raise one or

more issues which the Deputy

Administrator finds warrant a hearing,

the Deputy Administrator shall order a

public hearing by notice in the Federal

Register, summarizing the issues to be

heard and setting the time for the

hearing.

The Office of Management and Budget

has determined that notices of aggregate

production quotas are not subject to

centralized review under Executive

Order 12866. This action has been

analyzed in accordance with the

principles and criteria contained in

Executive Order 13132, and it has been

determined that this matter does not

have sufficient federalism implications

to warrant the preparation of a

Federalism Assessment.

The Deputy Administrator hereby

certifies that this action will have no

significant impact upon small entities

whose interests must be considered

under the Regulatory Flexibility Act, 5

U.S.C. 601 et seq. The establishment of

aggregate production quotas for

Schedules I and II controlled substances

is mandated by law and by international

treaty obligations. The quotas are

necessary to provide for the estimated

medical, scientific, research and

industrial needs of the United States, for

export requirements and the

establishment and maintenance of

reserve stocks. While aggregate

production quotas are of primary

importance to large manufacturers, their

impact upon small entities is neither

negative nor beneficial. Accordingly, the

Deputy Administrator has determined

that this action does not require a

regulatory flexibility analysis.

Dated: September 27, 2000.

Julio F. Mercado,

Deputy Administrator.

[FR Doc. 00–25421 Filed 10–3–00; 8:45 am]

BILLING CODE 4410–09–M

NATIONAL SCIENCE FOUNDATION

Committee Management; Renewal

The NSF management official having

responsibility for the U.S. National

Assessment Synthesis Team (#5219) has

determined that renewing through

October 31, 2000, is necessary and in

the public interest in connection with

the performance of duties imposed upon

the Director, National Science

Foundation (NSF), by 42 USC 1861 et

seq. This determination follows

consultation with the Committee

Management Secretariat, General

Services Administration.

Authority for this Committee will

expire on October 31, 2000. For more

information, please contact Karen York,

NSF, at (703) 292–4387.

Dated: September 28, 2000.

Karen J. York,

Committee Management Officer.

[FR Doc. 00–25400 Filed 10–3–00; 8:45 am]

BILLING CODE 7555–01–M

NUCLEAR REGULATORY

COMMISSION

[Docket No. 50–213]

Connecticut Yankee Atomic Power

Company, et al., Haddam Neck Plant;

Notice of Public Meeting To Discuss

the Haddam Neck License Termination

Plan

The Nuclear Regulatory Commission

(NRC) is in receipt of and has made

available for public inspection and

comment the License Termination Plan

(LTP) for the Haddam Neck Plant (HNP)

located in Haddam, Connecticut. NRC’s

receipt of the HNP LTP and the LTP’s

availability for comment was noticed in

the Federal Register on August 23, 2000

(65 FR 51345). The subject of this notice

is to announce that NRC staff will

conduct a public meeting to discuss the

HNP LTP on Tuesday, October 17, 2000,

at 7:00 p.m. at Haddam—Killingworth

High School, Higganum, Connecticut.

Connecticut Yankee Atomic Power

Company (CYAPC, or the licensee)

announced permanent cessation of

power operations of HNP on December

5, 1996. In accordance with NRC

regulations, CYAPC submitted a PostShutdown Decommissioning Activities

Report (PSDAR) for HNP to the NRC on

August 22, 1997. The facility is

undergoing active decontamination and

dismantlement.

In accordance with 10 CFR

50.82(a)(9), all power reactor licensees

must submit an application for

termination of their license. The

application for termination of license